Topical antifungals
Executive Summary
FDA to issue revised clinical protocols to establish bioequivalence for topical antifungals, vaginal antifungals and tretinoin in 30 days, Office of Generic Drugs Acting Director Bruce Burlington, MD, told a Nov. 16 FDA workshop. The agency will review material presented at the workshop and issue revised protocols, which may be open for further comment. Industry members asked FDA to provide a definition of bioequivalence for topical antifungals; the acceptable confidence interval for response in clinical trials; and clearly defined clinical endpoints. A draft bioequivalence protocol was issued at the meeting and is available through the agency. . . .
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.